Candida Albicans Efflux Inhibitor Screening Results from Drug Repurposing Study

Table 3_Identification of efflux inhibitors through a drug repurposing strategy in Candida albicans.xlsx contains results from an in silico and in vitro screening study. The research screened 245 predicted membrane transport proteins and tested a subset of 59 drugs for efflux-modulating potential against Candida albicans. The dataset was authored by Débora Marques and last updated on 2026-05-18.

Use Cases

• Identify candidate efflux inhibitors based on in vitro screening results.
• Analyze the adjuvant effect of drugs like amlodipine and procainamide on fluconazole efficacy.
• Validate in silico drug repurposing predictions against experimental fluorometric assay data.
• Compare minimum inhibitory concentration (MIC) values for drugs like miltefosine against Candida albicans.

Strengths

• Dataset is based on a specific screening of 245 predicted membrane transport proteins.
• Results include quantitative measures such as MIC values and fold-change reductions for fluconazole.
• Data is openly licensed under CC-BY-4.0.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (12.8 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

In silico screening from DrugBank database followed by in vitro assays against Candida albicans ATCC 90028.

Freshness

Last updated 2026-05-18 05:31:27; freshness should be verified.